Accuray Inc. has agreed to buy TomoTherapy Inc. in a cash and stock deal worth approximately $277 million, the company said Monday.
Sunnyvale-based Accuray (NASDAQ: ARAY) will pay $4.80 per share in cash and stock for TomoTherapy (NASDAQ: TOMO), which markets cancer-radiation therapy systems.
No comments:
Post a Comment